X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
STN1011101, a preservative-free combination eye drop of tafluprost 0.0015% and timolol 0.5%. It is being developed for lowering intraocular pressure of patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Tafluprost,Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: STN1011101
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Tafluprost-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Thea Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
Under the deal, Théa Pharma acquired seven products including established glaucoma therapies Zioptan®, Cosopt®, Cosopt® PF, and Betimol®, along with Azasite®, Akten®, and the ocular surface repair agent AcellFX™.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Zioptan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Théa Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 09, 2022
Details:
The purchase will add seven established brands, including Akorn’s leading glaucoma therapy, Zioptan®, to Théa’s portfolio. Théa will also welcome Akorn’s nearly 50-person sales force, which Théa expects to expand in support of anticipated growth and launches of additional products in the U.S.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Zioptan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 28, 2022
Details:
Taflotan (tafluprost) is the first preservative-free prostaglandin F2α analogue approved for the treatment open-angle glaucoma and in the management of ocular hypertension.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Taflotan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2021
Details:
Taptiqom (tafluprost/timolol) is a PTGFR agonist which is being developed for statistical and clinically significant intraocular pressure (IOP) reductions in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).
Lead Product(s): Tafluprost,Timolol Maleate
Therapeutic Area: Ophthalmology Product Name: Taptiqom
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
